The Bionics Institute is internationally renowned. It has a 30-year track record of excellence in clinically focused hearing research and development (R&D). It specialises in custom device design and fabrication, pre-clinical, safety and efficacy testing of devices, imaging, novel drug-delivery systems, psychophysical testing, 'first in human trials', gene therapy and clinical research/testing.
The Institute is highly experienced at partnering with industry in a number of ways, including via collaborative partnerships or through the provision of contract research services.
CILcare is a unique preclinical CRO fully dedicated to hearing. Based in France and in Boston, MA, CILcare supports biotechs and industries across the world to build comprehensive R&D program to develop novel therapies to treat hearing loss, tinnitus, and otitis, which affect 15% of the global population.
Pre-clinical services include in-vitro and in-vivo pharmacological models to assess the exposure, efficacy, and ototoxicity of drug candidates and medical devices.
NIHR Nottingham Biomedical Research Centre
Our partners at the Nottingham Biomedical Research Centre are experts in a range of disciplines, including Ear, Nose and Throat (ENT), audiology, health psychology and cognitive psychology. The centre's research interest in hearing spans the whole spectrum, from mild to profound degrees of hearing loss. It has specific interests in hearing-related conditions such as tinnitus and hyperacusis.
Nottingham BRC's National Institute for Health Research (NIHR) infrastructure funding supports early-phase clinical research, with interests in robust clinical-trial design. Find out more about the facilities and access to state-of-the-art research equipment.
The NIHR UCL Hospitals Biomedical Research Centre Deafness and Hearing Problems
The NIHR UCLH BRC Deafness and Hearing Problems Theme builds on the unique partnership of the UCL Ear Institute and UCLH Royal National Throat, Nose and Ear Hospital; this partnership provides the infrastructure and excellence to develop, test and deliver targeted and transformative hearing therapies.
Our state-of-the-art facilities and expertise ranges from molecular analysis, cellular imaging, brain electrophysiology, to auditory functional testing. Our expert ENT surgeons and hearing specialists, working in dedicated clinical research rooms at the Royal National Throat, Nose and Ear Hospital, ensure our trials are delivered efficiently and to the highest standard. Our evidENT team within the Ear Institute bridges our discovery science and clinical competencies by providing excellence in translational research. evidENT’s experience spans from first-in-man trial design through to implementation science, making the team the go-to place for pharma, biotech and device companies seeking to take their novel hearing approaches into the clinical domain.
NIHR Manchester Biomedical Research Centre
NIHR Manchester Biomedical Research Centre’s Hearing Health researchers are world leading in the development of new tests and treatments that improve people’s lives. They are tackling hearing loss from birth to older ages.
Multidisciplinary expertise includes audiology, hearing science, ENT, engineering and signal processing, biomaterials, auditory genetics, health psychology, health informatics, biomarkers, child development and communication.
The UK’s only Hearing Device Research Centre, Manchester Biomedical Research Centre offers consultancy services for translational and applied research. It also provides expertise in audiology healthcare education and training and bespoke Clinical Research Facilities for adults and children.
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients. The new name reflects the charity’s purpose: to be the arc or bridge between research and improving patients’ lives.
LifeArc is pioneering new ways to turn great science into greater patient impact. It brings together a network of partners to tackle specific diseases and directly funds academic and early stage research.
So far, LifeArc’s work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antimicrobial resistance.